Drug intelligence / Profile preview

AT-001

Development stage
Unknown
Lead developer
Applied Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

AT-001 is a specialized selenium-enriched yeast formulation developed by Alltech Life Sciences for the treatment of Alzheimer's disease. Unlike inorganic selenium salts, AT-001 provides selenium in an organic form, primarily selenomethionine, produced through a proprietary fermentation process using *Saccharomyces cerevisiae*. This organic form is highly bioavailable and serves as a precursor for the synthesis of essential selenoproteins, including glutathione peroxidase (GPx) and thioredoxin reductase (TrxR). These enzymes are critical components of the brain's antioxidant defense system, neutralizing reactive oxygen species and protecting neurons from oxidative damage. AT-001 has been evaluated in Phase 1 clinical trials to assess its safety and its ability to reduce brain oxidative stress in healthy elderly volunteers, with the goal of slowing the neurodegenerative processes associated with Alzheimer's disease.

Brand names
Sel-Plex
Other names
Selenium-enriched yeastYeast-seleniumSel-Plex
02

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on AT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-001.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call